当前位置: 首页 >> 检索结果
4581. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
作者: Holger Reinecke.;Christiane Engelbertz.;Rupert Bauersachs.;Günter Breithardt.;Hans-Herbert Echterhoff.;Joachim Gerß.;Karl Georg Haeusler.;Bernd Hewing.;Joachim Hoyer.;Sabine Juergensmeyer.;Thomas Klingenheben.;Guido Knapp.;Lars Christian Rump.;Hans Schmidt-Guertler.;Christoph Wanner.;Paulus Kirchhof.;Dennis Goerlich.
来源: Circulation. 2023年147卷4期296-309页
Non-vitamin K oral anticoagulants have become the standard therapy for preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF). The effectiveness and safety of non-vitamin K oral anticoagulants in patients on hemodialysis is not well known.
4582. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
作者: Hongyi Wu.;Lili Xu.;Xin Zhao.;Huanyi Zhang.;Kang Cheng.;Xiaoyan Wang.;Manhua Chen.;Guangping Li.;Jiangnan Huang.;Jun Lan.;Guanghe Wei.;Chi Zhang.;Yinman Wang.;Juying Qian.;Junbo Ge.; .
来源: Circulation. 2023年147卷3期212-222页
Dual antiplatelet therapy (DAPT) with aspirin as a background therapy has become the standard care after percutaneous coronary intervention. However, some adverse noncardiac effects limited the use of aspirin in clinical practice. Thus, evaluation of pharmacological alternatives to aspirin is attractive. Previous data indicated that indobufen could lessen the unwanted side effects of aspirin while retaining the antithrombotic efficacy, but its combination with a P2Y12 inhibitor still lacks randomized clinical trial evidence.
4583. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
作者: Milind Y Desai.;Anjali Owens.;Jeffrey B Geske.;Kathy Wolski.;Sara Saberi.;Andrew Wang.;Mark Sherrid.;Paul C Cremer.;Srihari S Naidu.;Nicholas G Smedira.;Hartzell Schaff.;Ellen McErlean.;Christina Sewell.;Aarthi Balasubramanyam.;Kathy Lampl.;Amy J Sehnert.;Steven E Nissen.
来源: Circulation. 2023年147卷11期850-863页
Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) examined the effect of mavacamten on the need for SRT through week 32 in oHCM.
4584. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
作者: Kim A Connelly.;C David Mazer.;Pankaj Puar.;Hwee Teoh.;Chao-Hung Wang.;Tamique Mason.;Farhad Akhavein.;Ching-Wen Chang.;Min-Hui Liu.;Ning-I Yang.;Wei-Siang Chen.;Yu-Hsiang Juan.;Erika Opingari.;Yaseen Salyani.;William Barbour.;Aryan Pasricha.;Shamon Ahmed.;Andrew Kosmopoulos.;Raj Verma.;Michael Moroney.;Ehab Bakbak.;Aishwarya Krishnaraj.;Deepak L Bhatt.;Javed Butler.;Mikhail N Kosiborod.;Carolyn S P Lam.;David A Hess.;Otavio Rizzi Coelho-Filho.;Myriam Lafreniere-Roula.;Kevin E Thorpe.;Adrian Quan.;Lawrence A Leiter.;Andrew T Yan.;Subodh Verma.
来源: Circulation. 2023年147卷4期284-295页
Sodium-glucose cotransporter 2 inhibitors have been demonstrated to promote reverse cardiac remodeling in people with diabetes or heart failure. Although it has been theorized that sodium-glucose cotransporter 2 inhibitors might afford similar benefits in people without diabetes or prevalent heart failure, this has not been evaluated. We sought to determine whether sodium-glucose cotransporter 2 inhibition with empagliflozin leads to a decrease in left ventricular (LV) mass in people without type 2 diabetes or significant heart failure.
4585. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
作者: Pieter Martens.;Jeroen Dauw.;Frederik H Verbrugge.;Petra Nijst.;Evelyne Meekers.;Silvio Nunes Augusto.;Jozine M Ter Maaten.;Kevin Damman.;Alexandre Mebazaa.;Gerasimos Filippatos.;Frank Ruschitzka.;W H Wilson Tang.;Matthias Dupont.;Wilfried Mullens.
来源: Circulation. 2023年147卷3期201-211页
Acetazolamide inhibits proximal tubular sodium reabsorption and improved decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. It remains unclear whether the decongestive effects of acetazolamide differ across the spectrum of left ventricular ejection fraction (LVEF).
4586. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial.
作者: Petr Ostadal.;Richard Rokyta.;Jiri Karasek.;Andreas Kruger.;Dagmar Vondrakova.;Marek Janotka.;Jan Naar.;Jana Smalcova.;Marketa Hubatova.;Milan Hromadka.;Stefan Volovar.;Miroslava Seyfrydova.;Jiri Jarkovsky.;Michal Svoboda.;Ales Linhart.;Jan Belohlavek.; .
来源: Circulation. 2023年147卷6期454-464页
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used for circulatory support in patients with cardiogenic shock, although the evidence supporting its use in this context remains insufficient. The ECMO-CS trial (Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock) aimed to compare immediate implementation of VA-ECMO versus an initially conservative therapy (allowing downstream use of VA-ECMO) in patients with rapidly deteriorating or severe cardiogenic shock.
4587. The Prevalence and Association of Exercise Test Abnormalities With Sudden Cardiac Death and Transplant-Free Survival in Childhood Hypertrophic Cardiomyopathy.
作者: Jennifer Conway.;Sandar Min.;Chet Villa.;Robert G Weintraub.;Stephanie Nakano.;Justin Godown.;Mark Tatangelo.;Kathryn Armstrong.;Marc Richmond.;Beth Kaufman.;Ashwin K Lal.;Seshadri Balaji.;Alyssa Power.;Nathanya Baez Hernandez.;Letizia Gardin.;Paul F Kantor.;John J Parent.;Peter F Aziz.;John L Jefferies.;Andreea Dragulescu.;Aamir Jeewa.;Lee Benson.;Mark W Russell.;Robert Whitehill.;Joseph Rossano.;Taylor Howard.;Seema Mital.
来源: Circulation. 2023年147卷9期718-727页
Hypertrophic cardiomyopathy (HCM) can be associated with an abnormal exercise response. In adults with HCM, abnormal results on exercise stress testing are predictive of heart failure outcomes. Our goal was to determine whether an abnormal exercise response is associated with adverse outcomes in pediatric patients with HCM.
4588. Impact of Patient-Reported Outcome Measurement in Heart Failure Clinic on Clinician Health Status Assessment and Patient Experience: A Substudy of the PRO-HF Trial.
作者: Alexander T Sandhu.;Jimmy Zheng.;Neil M Kalwani.;Anshal Gupta.;Jamie Calma.;Megan Skye.;Roy Lan.;Brian Yu.;John A Spertus.;Paul A Heidenreich.
来源: Circ Heart Fail. 2023年16卷2期e010280页
Clinicians typically estimate heart failure health status using the New York Heart Association Class, which is often discordant with patient-reported health status. It is unknown whether collecting patient-reported health status improves the accuracy of clinician assessments.
4589. Social and Psychosocial Determinants of Racial and Ethnic Differences in Cardiovascular Health in the United States Population.
作者: Nilay S Shah.;Xiaoning Huang.;Lucia C Petito.;Michael P Bancks.;Hongyan Ning.;Natalie A Cameron.;Kiarri N Kershaw.;Namratha R Kandula.;Mercedes R Carnethon.;Donald M Lloyd-Jones.;Sadiya S Khan.
来源: Circulation. 2023年147卷3期190-200页
Social and psychosocial factors are associated with cardiovascular health (CVH). Our objective was to examine the contributions of individual-level social and psychosocial factors to racial and ethnic differences in population CVH in the NHANES (National Health and Nutrition Examination Surveys) 2011 to 2018, to inform strategies to mitigate CVH inequities.
4590. Transcatheter Mitral Paravalvular Leak Closure Using Arteriovenous Rail Across Aortic Bileaflet Mechanical Prosthesis: Multimodality Imaging Approach.
作者: Alessandro Beneduce.;Marco Bruno Ancona.;Filippo Russo.;Luca Angelo Ferri.;Barbara Bellini.;Ciro Vella.;Vittorio Romano.;Francesco Ancona.;Eustachio Agricola.;Matteo Montorfano.
来源: Circ Cardiovasc Imaging. 2023年16卷3期e014267页 4592. A Human Hereditary Cardiomyopathy Shares a Genetic Substrate With Bicuspid Aortic Valve.
作者: Marcos Siguero-Álvarez.;Alejandro Salguero-Jiménez.;Joaquim Grego-Bessa.;Jorge de la Barrera.;Donal MacGrogan.;Belén Prados.;Fernando Sánchez-Sáez.;Rebeca Piñeiro-Sabarís.;Natalia Felipe-Medina.;Carlos Torroja.;Manuel José Gómez.;María Sabater-Molina.;Rubén Escribá.;Ivonne Richaud-Patin.;Olalla Iglesias-García.;Mauro Sbroggio.;Sergio Callejas.;Declan P O'Regan.;Kathryn A McGurk.;Ana Dopazo.;Giovanna Giovinazzo.;Borja Ibañez.;Lorenzo Monserrat.;José María Pérez-Pomares.;Fátima Sánchez-Cabo.;Alberto M Pendas.;Angel Raya.;Juan R Gimeno-Blanes.;José Luis de la Pompa.
来源: Circulation. 2023年147卷1期47-65页
The complex genetics underlying human cardiac disease is evidenced by its heterogenous manifestation, multigenic basis, and sporadic occurrence. These features have hampered disease modeling and mechanistic understanding. Here, we show that 2 structural cardiac diseases, left ventricular noncompaction (LVNC) and bicuspid aortic valve, can be caused by a set of inherited heterozygous gene mutations affecting the NOTCH ligand regulator MIB1 (MINDBOMB1) and cosegregating genes.
4593. Intravascular Ultrasound and Multidetector Computed Tomography Imaging of Polymethylmethacrylate Cement Leakage Inducing Inferior Vena Cava Thrombosis.
作者: Rei-Yeuh Chang.;Tsung-Hsien Chen.;Chu-Jen Kuo.;Han-Lin Tsai.
来源: Circ Cardiovasc Imaging. 2023年16卷2期e014527页 4594. Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure.
作者: Doron Aronson.;Yaacov Nitzan.;Sirouch Petcherski.;Evgeny Bravo.;Manhal Habib.;Daniel Burkhoff.;William T Abraham.
来源: Circ Heart Fail. 2023年16卷1期e009787页
Current treatment of fluid retention in heart failure relies primarily on diuretics. However, adequate decongestion is not achieved in many patients. We aimed to study the feasibility and short-term performance of a novel approach to remove fluids and sodium directly from the interstitial compartment by enhancing sweat rate.
4595. Noncanonical Form of ERAD Regulates Cardiac Hypertrophy.
作者: Erik A Blackwood.;Lauren F MacDonnell.;Donna J Thuerauf.;Alina S Bilal.;Victoria B Murray.;Kenneth C Bedi.;Kenneth B Margulies.;Christopher C Glembotski.
来源: Circulation. 2023年147卷1期66-82页
Cardiac hypertrophy increases demands on protein folding, which causes an accumulation of misfolded proteins in the endoplasmic reticulum (ER). These misfolded proteins can be removed by the adaptive retrotranslocation, polyubiquitylation, and a proteasome-mediated degradation process, ER-associated degradation (ERAD), which, as a biological process and rate, has not been studied in vivo. To investigate a role for ERAD in a pathophysiological model, we examined the function of the functional initiator of ERAD, valosin-containing protein-interacting membrane protein (VIMP), positing that VIMP would be adaptive in pathological cardiac hypertrophy in mice.
4596. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models.
作者: Richard G Lee.;Anne Marie Mazzola.;Maurine C Braun.;Colin Platt.;Scott B Vafai.;Sekar Kathiresan.;Ellen Rohde.;Andrew M Bellinger.;Amit V Khera.
来源: Circulation. 2023年147卷3期242-253页
VERVE-101 is an investigational in vivo CRISPR base-editing medicine designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic protein production, and thereby durably lower low-density lipoprotein cholesterol. We test the efficacy, durability, tolerability, and potential for germline editing of VERVE-101 in studies of nonhuman primates and a murine F1 progeny study.
4597. Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.
作者: Jacob B Pierce.;Zhen Li.;Melissa A Greiner.;Steven J Lippmann.;N Chantelle Hardy.;Xian Shen.;Mark Stampehl.;Robert J Mentz.;Larry A Allen.;Pamela N Peterson.;Gregg C Fonarow.;Emily C O'Brien.;Stephen J Greene.
来源: Circ Heart Fail. 2023年16卷1期e010176页 4598. RNA-Binding Protein LIN28a Regulates New Myocyte Formation in the Heart Through Long Noncoding RNA-H19.
作者: Vagner Oliveira Carvalho Rigaud.;Robert C Hoy.;Justin Kurian.;Clare Zarka.;Michael Behanan.;Isabella Brosious.;Jennifer Pennise.;Tej Patel.;Tao Wang.;Jaslyn Johnson.;Lindsay M Kraus.;Sadia Mohsin.;Steven R Houser.;Mohsin Khan.
来源: Circulation. 2023年147卷4期324-337页
Developmental cardiac tissue holds remarkable capacity to regenerate after injury and consists of regenerative mononuclear diploid cardiomyocytes. On maturation, mononuclear diploid cardiomyocytes become binucleated or polyploid and exit the cell cycle. Cardiomyocyte metabolism undergoes a profound shift that coincides with cessation of regeneration in the postnatal heart. However, whether reprogramming metabolism promotes persistence of regenerative mononuclear diploid cardiomyocytes enhancing cardiac function and repair after injury is unknown. Here, we identify a novel role for RNA-binding protein LIN28a, a master regulator of cellular metabolism in cardiac repair after injury.
4599. In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial.
作者: Vishal N Rao.;Anand Shah.;Jaime McDermott.;Stephanie G Barnes.;Evan M Murray.;Michelle D Kelsey.;Stephen J Greene.;Marat Fudim.;Adam D DeVore.;Chetan B Patel.;Michael A Blazing.;Cara O'Brien.;Robert J Mentz.
来源: Circ Heart Fail. 2023年16卷2期e010158页
Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) improves clinical outcomes and quality of life. Optimizing GDMT in the hospital is associated with greater long-term use in HFrEF. This study aimed to describe the efficacy of a multidisciplinary virtual HF intervention on GDMT optimization among patients with HFrEF admitted for any cause.
4600. Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure.
作者: Michael F Cosiano.;Andrew Vista.;Jie-Lena Sun.;Brooke Alhanti.;Josephine Harrington.;Javed Butler.;Randall C Starling.;Robert J Mentz.;Stephen J Greene.
来源: Circ Heart Fail. 2023年16卷1期e010107页
Alignment between clinician-reported New York Heart Association (NYHA) class compared and patient-reported outcomes among patients hospitalized for heart failure is unclear.
|